Development of Encorafenib for BRAF-mutated Advanced Melanoma

Current Opinion in Oncology - United States
doi 10.1097/cco.0000000000000426
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)